- September 2, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Cardiology » Coronary artery disease » Risk factors for coronary artery disease
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Cardiology » Coronary artery disease » Risk factors for coronary artery disease
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
2.5 mg orally each day initially
Double the dose every 2 weeks as tolerated up to 10 mg each day
Initially 0.6 mg subcutaneously once daily for 1 week
After a week, increase the dose to 1.2 mg subcutaneously once daily
Increase the dose to 1.8 mg
subcutaneously once daily
Maintenance dose- 1.2 to 1.8 mg each day
Maximum dose- 1.8 mg/day
Initially 0.6 mg subcutaneously once daily for 1 week
After a week, increase the dose to 1.2 mg subcutaneously once daily
Increase the dose to 1.8 mg subcutaneously once daily
Maintenance dose- 1.2 to 1.8 mg each day
Maximum dose- 1.8 mg/day
The drug is pending FDA approval
It helps in the reduction of death caused by cardiovascular failure
It is also indicated in patients with type 2 diabetes and a risk of heart failure with a worsening condition
Future Trends
References
ADVERTISEMENT
» Home » CAD » Cardiology » Coronary artery disease » Risk factors for coronary artery disease
2.5 mg orally each day initially
Double the dose every 2 weeks as tolerated up to 10 mg each day
Initially 0.6 mg subcutaneously once daily for 1 week
After a week, increase the dose to 1.2 mg subcutaneously once daily
Increase the dose to 1.8 mg
subcutaneously once daily
Maintenance dose- 1.2 to 1.8 mg each day
Maximum dose- 1.8 mg/day
Initially 0.6 mg subcutaneously once daily for 1 week
After a week, increase the dose to 1.2 mg subcutaneously once daily
Increase the dose to 1.8 mg subcutaneously once daily
Maintenance dose- 1.2 to 1.8 mg each day
Maximum dose- 1.8 mg/day
The drug is pending FDA approval
It helps in the reduction of death caused by cardiovascular failure
It is also indicated in patients with type 2 diabetes and a risk of heart failure with a worsening condition
Safety and efficacy are not seen in pediatrics
Refer to adult dosing
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.